Biosimilars Market
完整報告名稱與涵蓋範圍
Biosimilars Market Size, Share & Trends Analysis Report, By Molecule Type (Monoclonal Antibodies, Insulins, Erythropoietins, Granulocyte Colony-Stimulating Factors, Fusion Proteins, Growth Hormones), By Indication (Oncology, Autoimmune & Inflammatory Diseases, Diabetes, Blood Disorders, Ophthalmology), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
Biosimilars are follow-on biologics demonstrated to be highly similar to licensed reference products in quality, safety and efficacy, approved through abbreviated regulatory pathways in mature and emerging markets alike. This report spans biosimilar monoclonal antibodies, insulins, erythropoietins, colony-stimulating factors, fusion proteins and growth hormones across oncology, immunology, diabetes, haematology and ophthalmology, covering developers, in-licensors and commercial distributors while excluding the originator reference brands themselves.
Momentum comes from a dense calendar of patent expiries on blockbuster antibodies, most visibly the immunology and ophthalmology franchises whose loss of exclusivity has opened multi-competitor races within months of expiry. Payer pressure is equally decisive: tender systems in Europe, formulary interchangeability policies in the United States and national procurement in China and India reward steep discounting and reliable supply. Structural developments include interchangeability designations reducing pharmacy-level switching friction, streamlined regulatory science that trims comparative efficacy trial requirements, vertical integration by companies controlling their own drug substance capacity, and a widening cohort of Asian developers exporting globally.
Europe remains the most mature adoption environment thanks to a decade of tender-driven uptake, North America is the largest value opportunity as its policy environment matures, and Asia Pacific combines fast domestic uptake with growing export manufacturing strength. Competition is intense and moderately fragmented, mixing global generics leaders, Korean and Indian biologics specialists and originator companies running their own biosimilar units.
The InsightAce study delivers US$ revenue forecasts for all molecule, indication, distribution channel and regional segments over 2026-2035, with segment trend analysis, competitive landscape evaluation and company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biosimilars Market Snapshot
Chapter 4. Global Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Molecule Type Estimates & Trend Analysis
5.1. Molecule Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Molecule Type:
5.2.1. Monoclonal Antibodies
5.2.2. Insulins
5.2.3. Erythropoietins
5.2.4. Granulocyte Colony-Stimulating Factors
5.2.5. Fusion Proteins
5.2.6. Growth Hormones
5.2.7. Other Biosimilar Molecules
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Oncology
6.2.2. Autoimmune & Inflammatory Diseases
6.2.3. Diabetes
6.2.4. Blood Disorders
6.2.5. Ophthalmology
6.2.6. Other Indications
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. Distribution Channel & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Biosimilars Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Sandoz Group AG
10.2. Celltrion Inc.
10.3. Samsung Bioepis
10.4. Amgen Inc.
10.5. Pfizer Inc.
10.6. Viatris Inc.
10.7. Biocon Biologics
10.8. Teva Pharmaceutical Industries
10.9. Fresenius Kabi
10.10. Coherus BioSciences
10.11. STADA Arzneimittel AG
10.12. Dr. Reddy's Laboratories
10.13. Organon & Co.
10.14. Alvotech
10.15. Formycon AG
圖表清單 List of Tables & Figures
Table 1. Global Biosimilars Revenue Forecast by Molecule Type, 2026-2035 (US$ Mn)
Figure 1. Biosimilar Approval Timeline Across Major Regulatory Agencies
Table 2. Global Biosimilars Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Biosimilars Share by Molecule Type, 2026 & 2035
Table 3. Global Biosimilars Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 3. Upcoming Biologic Patent Expiry Calendar and Biosimilar Entry Windows
Table 4. North America Biosimilars Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Biosimilar Price Erosion and Uptake Curve Dynamics by Region
Table 5. Europe Biosimilars Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Biosimilars Growth Opportunity Analysis
Table 6. Asia Pacific Biosimilars Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Interchangeability and Substitution Policy Landscape by Country
Table 7. Latin America and Middle East & Africa Biosimilars Revenue, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Biosimilar Developers
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們